Market evolution: Sulfa drugs (CN 2935) — 2015–2025

Introduction

This report analyses the European Union's trade in sulphonamides (customs code 2935) with non-EU countries between 2015 and 2025. The data reveals a profound transformation in the EU's position, evolving from a major net exporter to a significant net importer. This shift is driven by a combination of collapsing exports, surging imports—particularly from Switzerland—and a reorientation of EU production towards higher-value activities. These dynamics have increased the EU's external dependency and altered the competitive landscape of the global sulphonamides market.

1. The Great Reversal: From Net Exporter to Net Importer

The most striking development over the decade is the complete reversal of the EU's trade balance. The bloc transitioned from a substantial net exporter to a significant net importer, a change quantifiable across all key metrics.

1.1 Trade Balance Swing from Surplus to Deficit

The EU's trade balance for sulphonamides deteriorated from a surplus of €2.12 billion in 2015 to a deficit of -€1.87 billion in 2025, representing a decline of -188.2% (Trade Balance). This structural shift is the central feature of the period.

1.2 Imports Quintuple in Value While Exports Collapse

The deficit was caused by two concurrent movements:

• Imports: Their value surged by 367.6%, from €744.7 million in 2015 to €3.48 billion in 2025.
• Exports: Their value plummeted by 43.8%, from €2.87 billion in 2015 to €1.61 billion in 2025.

While import volumes grew by 22.6%, the far larger value increase points to a rise in import unit prices, which climbed by 281.4% over the period. Export volumes fell by 12.8%, but the steeper drop in value (-43.8%) indicates an even sharper decline in export prices (-35.6%) (General Overview).

1.3 Switzerland as the Primary Catalyst for the Import Surge

The growth in imports was not evenly distributed. Switzerland became the dominant source, with imports from the country rising from €111.6 million in 2015 to €1.87 billion in 2025—a staggering increase of 1,578.6% (Top Partners by Value). By 2025, Switzerland accounted for over half of the value of all EU sulphonamides imports, a massive concentration given its non-EU status. This likely reflects transhipment or intra-company trade involving final pharmaceutical products classified under this chemical code.

2. Export Erosion and a Restructured Partner Portfolio

EU exports did not just shrink; their composition and destination profile changed significantly, indicating a loss of competitiveness in traditional markets and a pivot towards new or niche partners.

2.1 The US Market Collapse and Diversification Attempts

The United States, the EU's largest export partner in 2015 (€2.38 billion), saw its imports from the EU drop by 57.8% to €1.0 billion by 2025. This loss of the primary market was only partially offset by growth in exports to other partners. Exports to Japan grew by 308.4% to €62.4 million, to Switzerland by 370.5% to €72.2 million, and to Russia by 121.5% to €77.6 million (Top Partners by Value). Despite these increases, they remained small in absolute terms compared to the lost US business.

2.2 Increased Export Market Volatility

The search for new markets introduced greater volatility. The coefficient of variation (CV) in export values to partners like Switzerland (0.56), Japan (0.23), and Russia (0.38) was relatively high, indicating less stable trade flows compared to the previously dominant US link (CV 0.18) (Volatility & Shocks).

2.3 Domestic Export Concentration Shifts Internally

The source of EU exports within the bloc also changed. Ireland, historically the powerhouse exporter, saw its exports fall from €2.31 billion in 2015 to €0.80 billion in 2025 (-65.3%). Germany and Spain emerged as relatively stronger exporters, with Germany's exports growing by 211.1% to €237.3 million and Spain's by 122.6% to €67.6 million (Top Reporters by Value). This suggests a geographical and possibly product-based reconfiguration within the EU's production network.

3. Structural Shifts: Production, Prices, and Strategic Vulnerability

Behind the trade flows lie deeper changes in production strategies, price dynamics, and the EU's systemic exposure to external suppliers.

3.1 EU Production Shifts to Higher Value, Lower Volume

While EU production volume of sulphonamides declined by 16.3% (from 8,047,762 kg to 6,733,512 kg), its value increased by 42.0% (from €371.9 million to €528.0 million) (Production Quantity, Production Value). This indicates a move up the value chain, potentially focusing on more specialized or final-formulation sulphonamides. Ireland remains the most specialised producer, with a Revealed Symmetric Comparative Advantage (RSCA) of 0.92 (Most Specialised Reporters).

3.2 Asymmetric Price Dynamics and Shocks

Import and export prices moved in opposite directions. Import prices rose dramatically (+281.4%), while export prices fell (-35.6%). The data identifies significant price shocks: a 109.1% import price shock from the US in 2019 and a 54.6% shock from China in 2017 (Top Shock Events). These shocks, occurring in the context of a tightening market, contributed to the surge in import values.

3.3 Rising Import Concentration and Strategic Vulnerability

The market structure has become more concentrated and vulnerable. The Herfindahl-Hirschman Index (HHI) for import value rose from 2,186 in 2015 to 5,300 in 2025, indicating a move from a moderately concentrated market to one with high concentration, driven by Switzerland's dominance (Concentration HHI). Consequently, the EU's net import reliance soared from 12.2% to 72.2%, signifying a high and rapidly increasing dependence on foreign suppliers for this critical pharmaceutical precursor.

Conclusion

Between 2015 and 2025, the EU's sulphonamides market underwent a fundamental restructuring. The era of large-scale net exports ended, replaced by deep import dependence, primarily funnelled through Switzerland. EU producers responded by retreating from volume-driven exports, particularly to the US, and pivoting towards higher-value production. This transition, however, has created significant strategic vulnerabilities. The import side is now highly concentrated, exposed to price shocks, and represents a major trade deficit. The data suggests the EU has outsourced a substantial portion of the standard sulphonamides supply chain while attempting to specialise in more advanced, higher-margin segments—a high-stakes strategic gamble in a globally critical industry.